New VP of Clinical and Regulatory Affairs for Intec Pharma

Pnina Strauss-Levy has broad experience in clinical development, regulatory affairs and business development

Intec Pharma, a clinical-stage biopharmaceutical company based in Jerusalem, Israel, has appointed Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs.

Strauss-Levy has held several positions with Kamada, an Israeli pharmaceutical company, including Vice President, Clinical Development and IP. She has experience in clinical development, regulatory affairs and business development.

Strauss-Levy holds a BSc degree in Biochemistry and Food Sciences from the Hebrew University in Jerusalem and an MBA degree from the University of Derby in the UK.

Intec Pharma is developing drugs based on its proprietary Accordion Pill technology, an oral drug delivery system that aims to improve the efficacy and safety of existing drugs and drugs in development by using a gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for treating Parkinson's disease; Accordion Pill Zaleplon, or AP-ZP, which is being developed for treating insomnia, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers.

You may also like